In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Articles|December 13, 2021
Daily OTC Pearl: Blue Star Ointment
Author(s)Saro Arakelians, PharmD
Blue Star Ointment is used for skin issues such as itchiness, scaly, dry skin, eczema, rashes, ringworms, jock itch, and athlete’s foot.
Advertisement
OTC/Lifestyle Pearl of the Day: Blue Star Ointment
Indication: Blue Star Ointment is an OTC cream with
Insight:
- Blue Star Ointment is used for symptoms such as itchiness, scaly, dry skin, eczema, rashes, ringworms, jock itch, and athlete’s foot.
- It can relieve burning feeling and severe itchiness as well.
- Blue Star Ointment contains 1.2% camphor.
- The
American Academy of Dermatology Association recommends ointments or creams with camphor or menthol for relieving psoriasis-related itchiness. However, they also recommend using a moisturizer to counteract the drying effects of these products. - Patients should be advised to not get this in their eyes and to not ingest it.
Sources:
Advertisement
Related to this article
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
5